Geert van Tetering

📍Set scientific and technical strategy to develop antibody solutions for autoimmune diseases

📍Ensure operational excellence allowing smooth antibody development 🧬 FcR Therapeutics is developing first-in-class antibody solutions for autoimmune disease. Our proprietary drug leads can target Fc receptors (FcRs), a specific class of receptors expressed on various immune cells, to provide a major therapeutic perspective for patients suffering from various devastating autoimmune diseases

📍The right place for expert advice on the development of antibodies! 🌐 www.gtbiotechconsultancy.com 👉 See LinkedIn Projects (section below) for a selection of recent projects In my 20+ years of R&D experience, I have held several academic positions in expert centers in the Netherlands and abroad. In my commercial life I have worked in globally operating small biotech and large pharma companies in diverse roles. I gathered ample experience in the field of antibody development, immunotherapeutics, autoimmune disease and oncology. As a consultant I utilize my vast antibody knowledge and expertise to aid start-up and small to medium sized biotechs in various fields; from oncology, autoimmune-, to metabolic- or neurological disease. I offer advice on the development of therapeutic antibodies, manage R&D projects, and aid in scientific writing. 🧬 - Antibody development - GT Biotech Consultancy offers expert advice on pre-clinical antibody development. From early antibody discovery, lead optimisation to antibody production processes, but also on design of multi-specifics or other antibody-modality combinations 🧪 - R&D management - Your antibody R&D projects require full attention, to run smooth and efficient. With GT Biotech Consultancy your antibody development project is in good hands, no matter whether it is run in-house or outsourced elsewhere 🔎 - Technology evaluation - Do you have a particular antibody project that needs expert review? GT Biotech Consultancy is able to review novel assets, to scout innovations, and to explore emerging technologies. Happy to think along on exciting antibody projects. 👨🏻‍💻 - Scientific writing - Whether it is preparation of scientific reports, brief technical descriptions, data overviews or aid in pre-clinical development plans, GT Biotech Consultancy has ample experience in scientific writing. For antibody therapeutics, but also other projects Contact details ☎️ +31 (0)646 721 762 ✉️ info@gtbiotechconsultancy.com

📍Resilient Collective is a consulting group offering a holistic range of services tailored to meet the diverse needs of life sciences companies. Our network consists of expert consultants who specialize not only in scientific sectors such as biotech, pharmaceuticals, and healthcare but also in essential business functions like HR, administration, business development, and public relations. 💡We provide companies with comprehensive solutions that cover every aspect of their operations, from regulatory and strategic support to business growth, talent management, and effective communication. Resilient Collective combines the agility of independent consulting with the strength of a collaborative network, ensuring you receive targeted expertise across all areas crucial to your success. 🦸🏻 With consultants across Europe and a deep understanding of the life sciences landscape, we help our clients unlock innovation, drive operational efficiency, and achieve sustainable growth. 🤝 Partner with Resilient Collective for a 360-degree consulting experience, tailored to your company’s unique needs.

📍TigaTx is a US based biotech company exploring therapeutic options of IgA antibodies using its proprietary antibody technology. TigaTx’s R&D activities take place in Utrecht, The Netherlands. 🔖 Patents: - ENGINEERED IGA ANTIBODIES AND METHODS OF USE - WO/2025/029690 - ENGINEERED IGA ANTIBODIES AND METHODS OF USE - WO/2020/197400 - COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS - WO/2020/092427 📈Results: - Functional characterization of engineered antibodies - Generation of novel antibodies (phage display) - Set-up of discovery pipeline - Development of (analytical) assays - Improved process development - Nomination of lead antibody candidate - Selection of CDMO - Scientific reports 👤Direct reports: - 1 scientist - 2 technicians - 2 (sr) research associates

📍Harnessing the potential of IgA antibodies against cancer: Early-stage research focusing on the power of using IgA antibodies to battle cancer. 📑 Papers: - Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents - Antibodies - Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies? - Frontiers in Immunology - Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9 - Cancers - IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models - The Journal for ImmunoTherapy of Cancer - Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade - The Journal for ImmunoTherapy of Cancer - The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy - Cancer Immunology Immunotherapy 📈Results: - Engineered improved IgA antibodies & bispecific IgA antibodies - Production & purification process optimization - Quality Management System 🎓 Advisor: - Professor‘s right hand man - First source of information for group members - Co-promoter PhD student 👤Direct reports: - 1 PhD student - 3 technicians - 2 MSc students

📍Gadeta B.V. is a R&D company which focusses on the development of innovative immunotherapies for cancer based on the role of γδ T cell receptors (TCRs) in the broad recognition of both hematological and solid tumors 📈Results: - Design of novel TCRs - Set-up of molecular workflow - Optimized and improved viral production - Set-up of validation assay of transgene integration 👤Direct reports: - 4 technicians - 1 MSc student

📍Aristi Biotech is a Dutch contract research provider specialized in early antibody research and development activities. Aristi has a license to the CHOBC® platform to generate high quality and high titer manufacturing cell lines. 🔖 Patent: - T CELL-BASED BI-SPECIFIC IMMUNOTHERAPEUTICS - WO/2017/186853 📈Results: - Production and purification of various antibodies - Molecular design for novel bispecific antibody-like molecules 👤Direct reports: - 2 scientists

📍Direct the development and execution of immunoassays for the production processes of pembrolizumab (Keytruda) Global Vaccines & Biologics Commercialization Department of Analytical Development & Validation 📈Results: - Generation of HCP-specific antibodies - Organization of global Merck Science & Technology Days 👤Direct reports: - 5 scientists

📍Set-up and execute immunoassays for the production processes of pembrolizumab (Keytruda) Department of Analytical Development & Validation Method Development, Characterization & Process support Group 📈Results: - Set-up of 2D-DIGE assay - Optimization of immunoassays

📍Focus: Epigenetic regulation of RNA processing in leukemia Investigation on the RNA processsing events that are suppressed by DNA methylation and its impact on the development and maintenance of leukemia Laboratory of Dr. Manel Esteller Cancer Epigenetics and Biology Program (PEBC) Bellvitge Institute for Biomedical Research (IDIBELL) 📑 Paper: - Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia - Leukemia 👤Direct reports: - 2 Erasmus students

📍Focus: In vivo kinetics of therapeutic IgA antibodies in cancer Investigate the potential of IgA antibodies to inhibit or prevent cancer growth in vivo Laboratory of Dr. Jeanette Leusen Department of Immunology, UMC Utrecht 📑 Papers: - Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing - Cancer Immunology Research - Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice - Immunology Letters - IgA EGFR antibodies mediate tumor killing in vivo - EMBO Molecular Medicine 👤Direct reports: - 1 MSc student